CYP450遗传多态性:在故意过量服用素和美拉托宁后,发生泛性性-克隆性发作
Sarah Campbell1, Hannah Otten2,3, Vivek Anand2,4
1Psychiatry Residency Program, University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota.
概括
细胞染色体P450酶的遗传变异可以预测心理药物药物的严重副作用. 了解这些遗传多态度有助于个性化患者护理和过量管理.
科学领域:
- 药物遗传学 药物遗传学
- 临床药理学 临床药理学
- 毒理学 毒理学 毒理学
背景情况:
- 细胞染色体P450 (CYP450) 酶的遗传多态性在精神药物治疗中至关重要.
- 这些多态性显著影响药物代谢,导致药物动力学的患者间变异.
- 酶功能的降低可能与药物不良反应的风险增加有关.
研究的目的:
- 强调CYP450遗传多态性在预测故意过量后毒性表型方面的重要性.
- 探索基因型鉴定在预测心理药物严重副作用方面的实用性.
主要方法:
- 对CYP450多态性和精神药理学结果的现有文献的审查和综合.
- 突出基因测试在临床环境中的潜力.
主要成果:
- 功能较差的CYP450基因型与更高的副作用负担有关.
- 过量服用后,遗传多态化可以作为与毒性相关的表型的预测标记.
结论:
- 对CYP450多态的基因定型可以帮助预测严重的不良事件.
- 这些信息可以使临床医生能够提供更好的患者教育,实施有针对性的监测,并启动预防性治疗.
相关概念视频
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
186
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
186
Sedatives and Hypnotics Drugs: Miscellaneous Agents
196
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
196
Antiepileptic Drugs: Potassium Channel Activators
203
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
203
Antidepressant Drugs: MAOIs and Other Agents
266
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
266
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
332
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
332
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
428
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
428


